BOM:530239

1 story mentioning BOM:530239Updated 53d ago

Every FINWIRES story that references BOM:530239, newest first.

Suven Life Sciences Logs 76% Patient Enrollment Rate for Phase 3 Alzheimer's Drug Study

Suven Life Sciences' (NSE:SUVEN, BOM:530239) global phase 3 study for Masupirdine in agitation associated with Alzheimer's dementia achieved 76% patient enrollment.The 375-patient study is being conducted across Europe and North America, according to a Tuesday filing on Indian bourses.Patient enrollment is expected to be complete by September 2026, with data readout targeted for April 2027.

BOM:530239NSE:SUVEN

Track with the FINWIRES app suite

FolioX

Track BOM:530239 in your portfolio

WheelAI

Analyze BOM:530239 options with the wheel strategy

StockInsider

See market sentiment on BOM:530239